Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase InhibitorClin. Cancer Res 2022 Jan 03;[EPub Ahead of Print], JÁ García-Sáenz, N Martínez-Jáñez, R Cubedo, Y Jerez, A Lahuerta, S González-Santiago, N Ferrer, M Ramos, JL Alonso-Romero, A Antón, E Carrasco, J Chen, R Neuwirth, K Galinsky, S Vincent, EJ Leonard, D Slamon
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.